Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT07741929

Patient and Provider Perspectives on Genetic Risk Profiling

Patient and Provider Perspectives on Genetic Risk Profiling — Recruiting • Oncology • NCT07741929.

📅 03 Aug 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT07741929
Sponsor
Royal Marsden NHS Foundation Trust
Start
2026-05-01
ClinicaliQ Trial Snapshot
  • Patient and Provider Perspectives on Genetic Risk Profiling — Recruiting • Oncology • NCT07741929.
  • What is being tested: Patient and healthcare provider perspectives on the clinical utility and practical application of genetic risk profiling when integrated into routine clinical practice, explored through qualitative interviews.
  • Patient eligibility overview: The study recruits patients who have undergone or are eligible for genetic risk profiling, alongside healthcare providers involved in delivering or interpreting genetic risk assessments in clinical settings.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

A qualitative interview study exploring the patient and provider perspectives on the clinical utility of genetic risk profiling in routine clinical practice. The findings from the study may contribute towards future research and informing clinical practice.

Eligibility Snapshot
  • : * Individuals assigned male at birth who are aged 18 and over and who have capacity to consent * Patients who have undergone genetic risk profiling for prostate cancer and have received their results * Individuals from diverse backgrounds (age, ethnicity, risk status, etc) * Healthcare providers who have delivered a genetic risk profiling result for prostate cancer

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
‘My cancer spread while I waited months for surgery’: The cost of England’s cancer wait times
Oncology · BBC Health · 10 Sep 2026
England's cancer surgery waiting times have deteriorated despite government initiatives aimed at improving them, with patients experiencing significant delays that may allow…
View brief →
Clinical Brief
Wellbeing support demand for cancer patients grows
Oncology · BBC Health · 25 Oct 2026
Key Takeaways for Clinical Practice Cancer patients are reporting increased demand for wellbeing support services, suggesting current provision may not meet patient…
View brief →
Clinical Brief
New hope for breast cancer patients as life-extending drug now on NHS in England
Oncology · BBC Health · 16 Sep 2026
Enhertu is now available on the NHS in England, extending median overall survival by approximately seven months in eligible breast cancer patients…
View brief →
Guideline
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy
Oncology · 07 Oct 2026
Trastuzumab deruxtecan is recommended by NICE as a treatment option for HER2-low metastatic or unresectable breast cancer, making it suitable for patients…
View guideline →
Clinical Brief
The Irish international rugby ‘trailblazer’ and her legacy of cancer awareness
Oncology · BBC Health · 30 Sep 2026
A prominent Irish rugby player's death from breast cancer highlights the importance of raising awareness about symptoms among younger women, even in…
View brief →
Guideline
Ibrutinib with R-CHOP for untreated mantle cell lymphoma when a stem cell transplant is suitable
Oncology · 23 Sep 2026
Ibrutinib combined with R-CHOP is recommended for untreated mantle cell lymphoma patients who are fit enough to undergo stem cell transplantation, offering…
View guideline →